NCT00496821View on ClinicalTrials.gov

Intranasal ALN-RSV01 Administered to Adult Volunteers Experimentally Inoculated With Respiratory Syncytial Virus

PHASE2CompletedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

July 31, 2007

Study Completion Date

November 30, 2007

Conditions
Respiratory Syncytial Virus Infections
Interventions
DRUG

ALN-RSV01

Trial Locations (1)

02142

Alnylam Pharmaceuticals, Cambridge

Sponsors
All Listed Sponsors
lead

Alnylam Pharmaceuticals

INDUSTRY